Wednesday - December 25, 2024
WARSAW, Ind., Dec. 04, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced plans to host educational and networking events at IPOS and its increased support of the event as an Emerald-Level sponsor. IPOS, a branch of the Pediatric Orthopedic Society of North America (POSNA), is a leading educational meeting for pediatric orthopedic surgeons. Over 500 pediatric orthopedic surgeons are registered to attend the meeting from December 5-9, in Orlando, Florida.
“We are extremely excited to connect with our surgeon customers and continue to partner with them in education, through hands-on experience with our expanding product portfolio,” said David Bailey, President and CEO of OrthoPediatrics. “I am particularly proud of our continued partnership with POSNA because we share the same goal, to continue to help more kids by advancing the field of pediatric orthopedics.”
In addition to the booth (#15), wherein the Company will highlight their full suite of products, and feature 7D, 3-D Side and the new Specialty Bracing division (OPSB), the Company is hosting several educational experiences for surgeons and other allied health professionals. OrthoPediatrics IPOS 2023 Events include:
Pre-course
Industry Spotlight Sessions
About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 53 products that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 70 countries outside the United States. For more information, please visit www.orthopediatrics.com.
Investor Contacts
Philip Trip Taylor
Gilmartin Group
philip@gilmartinir.com
Last Trade: | US$22.58 |
Daily Change: | -0.05 -0.22 |
Daily Volume: | 104,597 |
Market Cap: | US$546.770M |
November 26, 2024 November 06, 2024 August 05, 2024 August 05, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB